How much time should I budget?

About 3 hours total, a working session and a review call. We do the heavy lifting.

What if I only want the roadmap, not the build?

That's the Campaign Repositioning Sprint. Ship it yourself, or upgrade to Done-For-You later.

Do you interview my customers?

Optional. We can mine your call recordings, reviews, and won/lost notes instead.

B2B teams spending $20K+/mo on ads whose demos aren't converting.

Book a 30-minute call. We'll tell you straight if it's a fit.

Where Evaluate's ads lose the buyer

Evaluate is running 23 live ads on LinkedIn and Google. Their average fit to their own ideal buyer is 7 out of 10, and 0 ads need fixing. Each ad below is one of Evaluate’s real live creatives, read straight from the ad libraries.

Evaluate’s live ads, scored against their buyer

Discover how the 2026 Preview reveals the forces shaping pharma’s most critical year, scored 7/10 against Evaluate’s ideal buyer. Strong ICP hook on patent cliffs and competition, but promise stays broad with no specific data teaser.
Discover how AI is actually being used in pharma forecasting, scored 7/10 against Evaluate’s ideal buyer. AI-in-forecasting angle hits a live pain for the ICP, but the report title on the creative is generic and no finding is surfaced to earn the click.
Benchmark your LBE against industry best practice, scored 8/10 against Evaluate’s ideal buyer. Specific LBE variance chart gives forecasting buyers a concrete, recognizable pain with real data shown on the creative.
Discover how the 2026 Preview reveals the forces shaping pharma’s most critical year, scored 6/10 against Evaluate’s ideal buyer. Strong ICP topic but headline stays vague where specific forces or data would earn the click.
Benchmark your LBE against industry best practice, scored 8/10 against Evaluate’s ideal buyer. Rare specificity on LBE variance analysis hits the forecasting leader's exact operational pain.
Discover how the 2026 Preview reveals the forces shaping pharma’s most critical year, scored 6/10 against Evaluate’s ideal buyer. Same report as ad 0 with a city skyline creative that adds no pharma signal or urgency.
Discover how AI is actually being used in pharma forecasting, scored 7/10 against Evaluate’s ideal buyer. AI plus forecasting plus 2026 trends lands squarely on the forecasting leader's current agenda.
See what is holding commercial AI back, and how to move forward, scored 8/10 against Evaluate’s ideal buyer. Three concrete survey stats on the creative make the AI-in-pharma tension immediately credible and clickable.
Explore how pharma forecasting teams are doing more with less, scored 6/10 against Evaluate’s ideal buyer. Headline angle of doing more with less is relatable but too generic to separate this from any ops report.
See what is holding commercial AI back, and how to move forward, scored 8/10 against Evaluate’s ideal buyer. Creative leads with a sharp tension, 'AI is everywhere, defensible AI is not,' backed by visible proof stats.
Explore how the 2026 Preview identifies tomorrow’s pharma winners and losers, scored 7/10 against Evaluate’s ideal buyer. Winners-and-losers framing sharpens the competitive intelligence angle, and the report preview shows real data tables.
Explore how pharma forecasting teams are doing more with less, scored 7/10 against Evaluate’s ideal buyer. Strong role and topic fit, but lead with the insight not the process description.
Portfolio Strategy Medtech Decision Making, scored 7/10 against Evaluate’s ideal buyer. Hits portfolio strategy and medtech buyers directly, but body stays generic on how data helps.
Maximize Pharma Business With Data, scored 7/10 against Evaluate’s ideal buyer. BD and licensing sitelink sharpens relevance, but headline outcome is broad and unproven.
Consensus Forecast Industry Standard, scored 8/10 against Evaluate’s ideal buyer. Consensus forecast headline names the exact ICP artifact, and sitelinks cover all core use cases.
Custom Analysis Medtech Strategy, scored 6/10 against Evaluate’s ideal buyer. Custom analysis angle is relevant but vague, and body copy does not advance the specific pain.
Maximize Pharma Business With Data, scored 5/10 against Evaluate’s ideal buyer. Headline is on-category but too broad, and no sitelinks or specifics anchor the value for the buyer.
Accelerate Asset Partnering AI Visibility, scored 8/10 against Evaluate’s ideal buyer. AI-powered deal evaluation headline maps precisely to BD and licensing pain, sitelinks reinforce all use cases.
AI Commercial Visibility Pharma Data, scored 7/10 against Evaluate’s ideal buyer. AI commercial visibility headline is compelling but paired headline dilutes focus across two promises.
Portfolio Strategy Custom Analysis Ad, scored 7/10 against Evaluate’s ideal buyer. Hits portfolio strategy, consensus forecasts, BD and competitive intel in one scan, but body copy stays generic.

See Evaluate’s full live-ad board on AdRoast. Every creative scored against their ICP, with the exact fix for each.

Learn the method behind these scores: the AdRoast guides cover how to audit your ads against your ICP and why clicks do not turn into pipeline.